Fig. 3

In Vivo Antitumor Activity of CD70 CAR-T Cells. 11C9 and 2A5 CAR-T cells treatment showed higher potency to eliminate tumor cell. A Schematic representation of the ACHN xenograft RCC model in NOG mice. Mice with complete responses after CAR-T cell treated group were re-challenged on day 101 with ACHN cells by S.C. to the flank of other side. B Tumor growth curve and C bodyweight changes of mice treated with CD70 CAR-T, non-transduced (NT), or vehicle control (Cell Cryopreservation Solution). Tumor volumes were compared by Student’s t test, **P < 0.01, ***P < 0.001, ****P < 0.0001. D The percentage of human CD3 + CD45 + cells in peripheral blood of mice detected by flow cytometry after CAR-T treatment. **P < 0.01, ****P < 0.0001 by Student’s t test. E Tumor volume after ACHN re-challenge and the percentage of human CD3 + CD45 + cells in individual mice of the 11C9 and 2A5 CAR-T treated group. After re-challenge, growing tumor cell in the other side of flank boosted CAR-T cell proliferation, then at least in part of mice of 11C9 treated mice, the tumor cell eradicated again